Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted Patients must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. No chemotherapy, radiotherapy, major surgery, or biologic therapy within weeks of protocol treatment Prior treatment: chemotherapy or radiotherapy or surgery History of receiving chemotherapy or radiotherapy Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within weeks before registration; patients who received prior radiotherapy to >= % of bone marrow are not eligible independent of when it was received Patient received radiotherapy, surgery, chemotherapy, or an investigational therapy within weeks prior to study entry localised breast cancer treated with surgery and radiotherapy but not including systemic chemotherapy; Any prior chemotherapy, surgery, or radiotherapy for EAC If a cancer survivor, the patient received prior systemic chemotherapy or radiotherapy Patients who have had prior chemotherapy or radiotherapy for the treatment of pancreas cancer Prior radiotherapy, surgery, chemotherapy, or hormonal therapy for prostate cancer Within days of completion of standard therapy (surgery, chemotherapy radiotherapy) No prior chemotherapy or radiotherapy for this malignancy Patients must not have received prior chemotherapy, radiotherapy, or antibody therapy for lymphoma Patients who have received any radiotherapy or chemotherapy for their current gynecological cancer Prior chemotherapy, radiotherapy, biological cancer therapy or major surgery within days prior to enrollment Patient must have received no prior radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease. Any treatment, including radiotherapy, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to study entry. The patient has received therapeutic dose chemotherapy or radiotherapy ? days prior to start of Investigational Product. No previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. No prior chemotherapy, radiotherapy, or antiangiogenic therapy Prior chemotherapy or radiotherapy Major surgery, chemotherapy, radiotherapy, investigational agents or other cancer therapy within week of treatment day Patient must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. Patients may have had prior therapy, including radiotherapy (systemic and/or cranial and/or spinal) or chemotherapy; at least days must have elapsed since completion of radiotherapy and days since completion of prior chemotherapy ( days for nitrosourea chemotherapy) No chemotherapy, radiotherapy, major surgery, or biologic therapy within weeks of protocol treatment Concurrent cancer chemotherapy, radiotherapy or surgery Received monoclonal antibodies (for any reason), chemotherapy, surgery, investigational therapy, or radiotherapy within days of the first dose of mogamulizumab; Received radiotherapy and temozolomide chemotherapy At least days since localized surgery, radiotherapy or chemotherapy All adverse events of any prior chemotherapy, surgery, or radiotherapy not resolved Major surgery, radiotherapy, chemotherapy or investigational agents within four weeks of treatment day Prior chemotherapy or radiotherapy for any brain tumor PATIENT ONLY: Patients must be within month of initiating or having undergone any type of cancer treatment (i.e., surgery, radiotherapy, chemotherapy) Diagnosis of cancer (any stage) for which active treatment (e.g., surgery, chemotherapy, and/or radiotherapy) has been completed within months to years Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancer Prior chemotherapy for SCCHN and/or radiotherapy to the region of the study cancer or Prior chemotherapy or radiotherapy Prior cancer chemotherapy or radiotherapy Patients who have received surgery alone or radiotherapy alone as definitive local therapy Women who have received cancer surgery, chemotherapy, biological therapy (e.g., trastuzumab), or radiotherapy for the treatment of any cancer within months of study participation Patient has received prior chemotherapy or radiotherapy for this cancer Prior chemotherapy or radiotherapy within the last three years Patient has received prior chemotherapy or radiotherapy for this cancer